Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.48 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294350 | 1.00 | PTGDR2 (0.48) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL28356264 | 0.87 | PTGDR2 (0.49) | PTGDR2RORC | |
| SCHEMBL21354238 | 0.87 | PTGDR2 (0.49) | PTGDR2RORC | |
| SCHEMBL17294222 | 0.86 | KCNH2 (0.54) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL17294221 | 0.86 | KCNH2 (0.54) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL17294336 | 0.85 | KCNH2 (0.50) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL17294337 | 0.85 | KCNH2 (0.50) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL17294288 | 0.84 | PTGDR2 (0.46) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL17294291 | 0.84 | PTGDR2 (0.46) | PTGDR2RORCENPP2CCR1KCNH2 | |
| SCHEMBL17295622 | 0.83 | RORC (0.47) | PTGDR2RORCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3148975-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197978-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | PTGDR2 555/4885RORC 1/4885ENPP2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.